The bull argument for Amarin's (NASDAQ:AMRN) Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback